Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial
Ezequiel Córdova, Jeniffer Hernández Rendon, Verónica Mingrone, Patricio Martin et autres